Authors
Latest:
The Transformative Role of Medical Information in Customer EngagementStacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Latest:
From Identity to Margin: Securing Audience Measurement in Pharma MarketingThe industry must find a way to balance consumer privacy and a return on investment in pharma marketing.
Latest:
Delivery and Disruption: Navigating a Changing Care TerrainThe diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
Latest:
By Any Genes Necessary: The Role of MEAs for Gene TherapiesExamining why the cost and administration of these treatments are well suited to managed entry agreements—and which approach to MEA may prove to be the most commercially viable for manufacturers.
Latest:
Primary Care in Crisis: PCP Navigation in a Specialty WorldCOVID-19 may be the latest challenge to primary care physicians, but it’s just one of many threatening the profession, including the increased focus on specialty drug markets—if PCPs are left out of the equation.
Latest:
When Will Payers Improve Coverage of Prescription Digital Therapeutics?New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.
Latest:
Delivering Medical Affairs Value Through Omnichannel OrchestrationLearnings from a roundtable discussion with Medical Affairs leadership from 11 pharma companies
Latest:
Labs and Computing Power: The Missing Link for a Revolution by 2030A shift in mindset to the experiment itself could lead the way.
Latest:
Elevating and De-Risking Your Drug Portfolio Strategy With AIArtificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.
Latest:
Advanced Analytical Characterization to Support Gene Therapy DevelopmentAn overview of trends in gene therapy, the unique analytical challenges posed by developing new treatments, and innovative solutions to address these challenges.
Latest:
Recent Developments in Pharmaceutical ValidationExplore the latest pharmaceutical validation developments with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, No deviation, and PCI. You’ll gain exclusive data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are reshaping the validation landscape.
Latest:
Engaging and Educating HCPs with KOL-Based Paid SocialHow non-endemic platforms can help brand teams amplify their use of KOLs in HCP outreach
Latest:
The Consolidated Appropriations Act and PBM TransparencyNew federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.
Latest:
It’s Time to Get Creative Hiring in a Post-Brexit European Life Sciences MarketBrexit and the pandemic continue to complicate flow of international talent.
Latest:
ESG: Applying Lessons From Consumer MarketA prime opportunity for pharma to raise its strategic game in ESG.
Latest:
Accelerating Market Access with Data-Driven Payer EngagementUsing data visualizations to improve access to payers.
Latest:
AI-Powered De-Identification and Data AnalysisAnita Kawatra discusses advancing clinical and pharmaceutical progress while protecting patient privacy.
Latest:
How a “Push and Pull” Approach Can Maximize Innovation Value through HTAsHow can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Latest:
How GxP Leaders Can Assess and Approach a Company’s Quality CultureUsing the interview process to ensure high organizational standards.
Latest:
How AI Is Carving UCB’s Path to Better Patient InsightsA look at how UCB is utilizing dynamic targeting via AI to improve overall patient experience.
Latest:
Using Service Design to Drive Value, Speed & Quality in the Regulatory Review ProcessNow regulatory review teams have found a way to accelerate their processes — processes not particularly suited to speed — without compromising quality, accuracy, or adherence to regulations, how can this pace be maintained as we emerge from the pandemic?
Latest:
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a CatchValue-based price for access (VBPA) may increase access of specialty drugs for patients.
Latest:
The Truth About TelemedicineScott Morano explores some of the challenging questions brands will need to ask in light of an HCP switch to telemedicine.
Latest:
When Innovation Outpaces HTA, Access Struggles to Keep UpScientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.
Latest:
The Rise of Longevity TherapeuticsThe field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.
Latest:
5 Digital Trends You Need to Adopt This Year to Remain Top of MindEnsure your tactical plan is up to the new, innovative standards that your audience expects from their digital experience with your brand.
Latest:
Changing the Paradigm in AI ImplementationHow pharma companies can reduce the risk of failure with AI-based innovations.
Latest:
How Market Access Can Determine Commercial SuccessUsing market access data from day one of your drug development and commercialization journey puts your brand in the best position to succeed at launch.
